Cholestanol derivative for combined use

Abstract

The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

What is claimed is: 
     
         1 . A cancer chemotherapeutic agent comprising, in combination, a cholestanol derivative represented by formula (1): 
       
         
           
           
               
               
           
         
       
       (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent. 
     
     
         2 . A cancer chemotherapeutic agent according to  claim 1 , wherein, in formula (1), G is GlcNAc-Gal- or GlcNAc-. 
     
     
         3 . A cancer chemotherapeutic agent according to  claim 1  or  2 , wherein the anti-cancer agent is one or more species selected from the group consisting of a taxane anti-cancer agent, a platinum complex anti-cancer agent, a pemetrexed compound, and fluorouracil. 
     
     
         4 . A cancer chemotherapeutic agent according to  claim 3 , wherein the anti-cancer agent is one or more species selected from the group consisting of Paclitaxel, Docetaxcel, Pemetrexed, 5-FU, Cisplatin, Oxaliplatin, Cyclophosphamide, and Irinotecan. 
     
     
         5 . A cancer chemotherapeutic agent according to any of  claims 1  to  4 , which is a compounding agent. 
     
     
         6 . A cancer chemotherapeutic agent according to any of  claims 1  to  4 , which is in the form of a kit including a drug containing a cholestanol derivative and a drug containing an anti-cancer agent. 
     
     
         7 . A cancer chemotherapeutic agent according to  claim 6 , wherein the drug containing a cholestanol derivative is a liposomal formulation. 
     
     
         8 . Use, in combination, of a cholestanol derivative represented by formula (1): 
       
         
           
           
               
               
           
         
       
       (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof and an anti-cancer agent, for producing a cancer chemotherapeutic agent. 
     
     
         9 . A cancer chemotherapy, characterized by comprising administering, in combination, a cholestanol derivative represented by formula (1): 
       
         
           
           
               
               
           
         
       
       (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof and an anti-cancer agent, to a patient in need thereof. 
     
     
         10 . A cancer chemotherapy according to  claim 9 , wherein the cholestanol derivative or a cyclodextrin inclusion compound thereof and the anti-cancer agent are administered to a patient in need thereof simultaneously, or separately and intermittently.